Table 3.
Comparisons of thyroid hormones in patients before and after WK* or sotalol treatments in the first investigation.
| Before treatments | |||
|---|---|---|---|
| WK* treatment (91 cases) | Sotalol treatment (89 cases) | t value (P value)** | |
| FT3* (pmol/L) | 24.613 ± 5.059 | 24.405 ± 5.006 | −0.278 (0.781) |
| FT4* (pmol/L) | 118.697 ± 29.213 | 116.132 ± 28.266 | −0.598 (0.550) |
| TSH* (μIU/mL) | 0.007 ± 0.010 | 0.009 ± 0.147 | 1.191 (0.235) |
|
| |||
| Three months after treatments | |||
| WK* treatment (91 cases) | Sotalol treatment (89 cases) | t value (P value)** | |
|
| |||
| FT3* (pmol/L) | 6.495 ± 3.713 | 6.596 ± 3.740 | 0.182 (0.855) |
| FT4* (pmol/L) | 21.447 ± 11.727 | 21.655 ± 10.612 | 0.125 (0.901) |
| TSH* (μIU/mL) | 6.210 ± 10.002 | 5.752 ± 8.915 | −0.324 (0.746) |
∗WK: Wenxin Keli, FT3: free triiodothyronine, FT4: free thyroxine, and TSH: thyroid stimulating hormone; **analyzed by independent samples t-test.